vs

Side-by-side financial comparison of Abacus Global Management, Inc. (ABX) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Abacus Global Management, Inc. is the larger business by last-quarter revenue ($71.9M vs $37.2M, roughly 1.9× Organogenesis Holdings Inc.). On growth, Abacus Global Management, Inc. posted the faster year-over-year revenue change (116.5% vs -57.1%). Over the past eight quarters, Abacus Global Management, Inc.'s revenue compounded faster (82.9% CAGR vs -46.5%).

Abacus Group is a ASX 200 public listed company that specialises in investing in Australian Real estate investment trusts with an investment portfolio concentrated in the Office and Self Storage sectors. They manage legacy investments in property developments. The company was known as Abacus Property Group until August 2023, when they split off their self-storage business, Abacus Storage King.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ABX vs ORGO — Head-to-Head

Bigger by revenue
ABX
ABX
1.9× larger
ABX
$71.9M
$37.2M
ORGO
Growing faster (revenue YoY)
ABX
ABX
+173.5% gap
ABX
116.5%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ABX
ABX
Annualised
ABX
82.9%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABX
ABX
ORGO
ORGO
Revenue
$71.9M
$37.2M
Net Profit
$7.2M
Gross Margin
88.8%
30.8%
Operating Margin
31.7%
-185.1%
Net Margin
10.1%
Revenue YoY
116.5%
-57.1%
Net Profit YoY
139.6%
EPS (diluted)
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABX
ABX
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$71.9M
$225.6M
Q3 25
$63.0M
$150.9M
Q2 25
$56.2M
$101.0M
Q1 25
$44.1M
$86.7M
Q4 24
$33.2M
$126.7M
Q3 24
$28.1M
$115.2M
Q2 24
$29.1M
$130.2M
Net Profit
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$7.2M
$43.7M
Q3 25
$7.1M
$21.6M
Q2 25
$17.6M
$-9.4M
Q1 25
$4.6M
$-18.8M
Q4 24
$-18.3M
$7.7M
Q3 24
$-5.1M
$12.3M
Q2 24
$770.0K
$-17.0M
Gross Margin
ABX
ABX
ORGO
ORGO
Q1 26
30.8%
Q4 25
88.8%
Q3 25
87.8%
Q2 25
89.2%
Q1 25
83.9%
72.6%
Q4 24
88.8%
75.5%
Q3 24
92.2%
76.7%
Q2 24
90.6%
77.6%
Operating Margin
ABX
ABX
ORGO
ORGO
Q1 26
-185.1%
Q4 25
31.7%
28.1%
Q3 25
35.6%
13.7%
Q2 25
40.1%
-12.5%
Q1 25
47.6%
-30.9%
Q4 24
-50.5%
8.1%
Q3 24
24.3%
5.4%
Q2 24
23.3%
-10.7%
Net Margin
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
10.1%
19.4%
Q3 25
11.2%
14.3%
Q2 25
31.3%
-9.3%
Q1 25
10.5%
-21.7%
Q4 24
-55.0%
6.1%
Q3 24
-18.2%
10.7%
Q2 24
2.6%
-13.1%
EPS (diluted)
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$0.06
$0.31
Q3 25
$0.07
$0.11
Q2 25
$0.18
$-0.10
Q1 25
$0.05
$-0.17
Q4 24
$-0.26
$0.05
Q3 24
$-0.07
$0.09
Q2 24
$0.01
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABX
ABX
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$38.1M
$91.4M
Total DebtLower is stronger
$405.8M
Stockholders' EquityBook value
$418.5M
Total Assets
$902.2M
$520.0M
Debt / EquityLower = less leverage
0.97×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABX
ABX
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$38.1M
$93.7M
Q3 25
$86.4M
$63.7M
Q2 25
$74.8M
$73.1M
Q1 25
$43.8M
$110.0M
Q4 24
$131.9M
$135.6M
Q3 24
$19.4M
$94.3M
Q2 24
$91.3M
$89.9M
Total Debt
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$405.8M
Q3 25
$409.3M
Q2 25
Q1 25
Q4 24
$380.8M
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$418.5M
$300.1M
Q3 25
$434.6M
$255.1M
Q2 25
$416.5M
$233.2M
Q1 25
$430.6M
$242.9M
Q4 24
$423.3M
$262.9M
Q3 24
$257.9M
$278.5M
Q2 24
$256.8M
$263.5M
Total Assets
ABX
ABX
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$902.2M
$598.7M
Q3 25
$918.9M
$509.8M
Q2 25
$848.4M
$461.1M
Q1 25
$856.5M
$467.4M
Q4 24
$874.2M
$497.9M
Q3 24
$477.3M
$446.3M
Q2 24
$483.9M
$443.2M
Debt / Equity
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
0.97×
Q3 25
0.94×
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABX
ABX
ORGO
ORGO
Operating Cash FlowLast quarter
$-25.7M
Free Cash FlowOCF − Capex
$-26.6M
FCF MarginFCF / Revenue
-37.0%
Capex IntensityCapex / Revenue
1.3%
Cash ConversionOCF / Net Profit
-3.55×
TTM Free Cash FlowTrailing 4 quarters
$-45.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$-25.7M
$39.4M
Q3 25
$-32.8M
$3.1M
Q2 25
$76.1M
$-32.9M
Q1 25
$-61.6M
$-19.9M
Q4 24
$-208.8M
$10.9M
Q3 24
$-52.3M
$8.7M
Q2 24
$-67.1M
$4.7M
Free Cash Flow
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
$-26.6M
$34.8M
Q3 25
$-32.9M
$844.0K
Q2 25
$75.7M
$-36.5M
Q1 25
$-61.8M
$-23.6M
Q4 24
$-209.6M
$7.6M
Q3 24
$-52.5M
$6.1M
Q2 24
$-67.2M
$2.9M
FCF Margin
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
-37.0%
15.4%
Q3 25
-52.3%
0.6%
Q2 25
134.6%
-36.1%
Q1 25
-140.0%
-27.2%
Q4 24
-631.1%
6.0%
Q3 24
-186.6%
5.3%
Q2 24
-231.3%
2.2%
Capex Intensity
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
1.3%
2.1%
Q3 25
0.3%
1.5%
Q2 25
0.8%
3.6%
Q1 25
0.5%
4.2%
Q4 24
2.4%
2.7%
Q3 24
0.9%
2.2%
Q2 24
0.7%
1.4%
Cash Conversion
ABX
ABX
ORGO
ORGO
Q1 26
Q4 25
-3.55×
0.90×
Q3 25
-4.63×
0.14×
Q2 25
4.33×
Q1 25
-13.28×
Q4 24
1.43×
Q3 24
0.71×
Q2 24
-87.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABX
ABX

Life Solutions Segment$63.0M88%
Asset Management Segment$8.7M12%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons